Vero Biotech
Atlanta
About Vero Biotech
Vero Biotech is a biopharmaceutical company focused on the design, development, and commercialization of next-generation products to address the unmet medical needs of patients with a variety of pulmonary and cardiac diseases. They are currently developing inhaled nitric oxide (NO) products for use in both the hospital setting and for longer-term applications outside of the hospital setting. These products, which are based on our GeNOsyl™ drug delivery technology, are comprised of a single-use drug cassette and either a portable console or wearable controller. Its technology is designed to deliver NO safely for a variety of therapeutic indications and to provide clinicians with a solution that is more user-friendly than currently available NO delivery systems.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $234.6M
- Last round: Series Unknown (Jan 2023)
- Website: vero-biotech.com
- Phone: 3217852460
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/vero-biotech-58557 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.